List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1540600/publications.pdf Version: 2024-02-01



Ειμ Ματειμιρα

#	Article	IF	CITATIONS
1	Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet, The, 1990, 336, 177-178.	6.3	620
2	Accelerated Atherosclerosis in Autoimmune Rheumatic Diseases. Circulation, 2005, 112, 3337-3347.	1.6	484
3	Association of autoantibodies against the phosphatidylserine–prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis and Rheumatism, 2000, 43, 1982-1993.	6.7	299
4	A role for interleukin-2 trans-presentation in dendritic cell–mediated T cell activation in humans, as revealed by daclizumab therapy. Nature Medicine, 2011, 17, 604-609.	15.2	267
5	Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1996, 39, 1466-1474.	6.7	210
6	Oxidation of LDL and its clinical implication. Autoimmunity Reviews, 2008, 7, 558-566.	2.5	195
7	Chemical Xenobiotics and Mitochondrial Autoantigens in Primary Biliary Cirrhosis: Identification of Antibodies against a Common Environmental, Cosmetic, and Food Additive, 2-Octynoic Acid. Journal of Immunology, 2005, 174, 5874-5883.	0.4	176
8	Circulating oxidized LDL forms complexes with \hat{l}^22 -glycoprotein I: implication as an atherogenic autoantigen. Journal of Lipid Research, 2003, 44, 716-726.	2.0	165
9	β2-Glycoprotein i reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis and Rheumatism, 1994, 37, 1453-1461.	6.7	150
10	Are Anti–Oxidized Low-Density Lipoprotein Antibodies Pathogenic or Protective?. Circulation, 2004, 110, 2552-2558.	1.6	143
11	Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Progress in Lipid Research, 2006, 45, 466-486.	5.3	143
12	ls atherosclerosis an autoimmune disease?. BMC Medicine, 2014, 12, 47.	2.3	122
13	Chronic Multiple Sclerosis Lesions: Characterization with High-Field-Strength MR Imaging. Radiology, 2012, 262, 206-215.	3.6	109
14	Translocator Protein PET Imaging for Glial Activation in Multiple Sclerosis. Journal of NeuroImmune Pharmacology, 2011, 6, 354-361.	2.1	98
15	Clinical significance of β2-glycoprotein I-dependent anticardiolipin antibodies in the reproductive autoimmune failure syndrome: Correlation with conventional antiphospholipid antibody detection systems. American Journal of Obstetrics and Gynecology, 1995, 172, 926-931.	0.7	93
16	Molecular definition of human β2-glycoprotein (α2-GPI) by cDNA cloning and inter-species differences of β2-GPI in alternation of anticardiolipin binding. International Immunology, 1991, 3, 1217-1221.	1.8	92
17	Binding of β2–glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood, 2005, 105, 1552-1557.	0.6	92
18	A chimeric antibody with the human ?1 constant region as a putative standard for assays to detect IgG ?2-glycoprotein I-dependent anticardiolipin and anti-?2-glycoprotein I antibodies. Arthritis and Rheumatism, 1999, 42, 2461-2470.	6.7	91

#	Article	IF	CITATIONS
19	Mutations in <i>MME</i> cause an autosomalâ€recessive Charcot–Marie–Tooth disease type 2. Annals of Neurology, 2016, 79, 659-672.	2.8	82
20	β2-glycoprotein I deficiency:. Atherosclerosis, 2000, 152, 337-346.	0.4	77
21	Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of patients with fungal or tuberculous meningoencephalitis. Journal of the Neurological Sciences, 2000, 173, 45-52.	0.3	75
22	OxLDL/β2GPI Complexes and Autoantibodies in Patients with Systemic Lupus Erythematosus, Systemic Sclerosis, and Antiphospholipid Syndrome: Pathogenic Implications for Vascular Involvement. Annals of the New York Academy of Sciences, 2005, 1051, 313-322.	1.8	71
23	Ϊ‰-Carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. Journal of Lipid Research, 2002, 43, 1486-1495.	2.0	64
24	The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. Journal of Lipid Research, 2007, 48, 768-781.	2.0	61
25	An association of IgG anti-laminin-1 autoantibodies with endometriosis in infertile patients. Human Reproduction, 2003, 18, 544-549.	0.4	60
26	Neuroimmunity of HTLV-I Infection. Journal of NeuroImmune Pharmacology, 2010, 5, 310-325.	2.1	60
27	Oxidized-LDL/β2-Glycoprotein I Complexes Are Associated With Disease Severity and Increased Risk for Adverse Outcomes in Patients With Acute Coronary Syndromes. American Journal of Clinical Pathology, 2010, 133, 737-743.	0.4	59
28	Hereditary sensory and autonomic neuropathy type IID caused by an <i>SCN9A</i> mutation. Neurology, 2013, 80, 1641-1649.	1.5	59
29	?2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis and Rheumatism, 1999, 42, 167-174.	6.7	58
30	Significance of valine/leucine247 polymorphism of ?2-glycoprotein I in antiphospholipid syndrome: Increased reactivity of anti-?2-glycoprotein I autoantibodies to the valine247 ?2-glycoprotein I variant. Arthritis and Rheumatism, 2005, 52, 212-218.	6.7	56
31	Nicked Â2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood, 2004, 103, 3766-3772.	0.6	54
32	Excessive exposure to anionic surfaces maintains autoantibody response to β2-glycoprotein l in patients with antiphospholipid syndrome. Blood, 2007, 110, 4312-4318.	0.6	52
33	Oxidized Low-Density Lipoprotein/β ₂ -Glycoprotein I Complexes and Autoantibodies to oxLig-1/β ₂ -Glycoprotein I in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. American Journal of Clinical Pathology, 2004, 121, 426-436.	0.4	51
34	Intracellular trafficking of β2-glycoprotein I complexes with lipid vesicles in macrophages: Implications on the development of antiphospholipid syndrome. Journal of Autoimmunity, 2007, 29, 164-173.	3.0	51
35	What is the "true" antigen for anticardiolipin antibodies?. Lancet, The, 1991, 337, 671-672.	6.3	50
36	Are Oxidized LDL/β2-glycoprotein I Complexes Pathogenic Antigens in Autoimmune-mediated Atherosclerosis?. Clinical and Developmental Immunology, 2004, 11, 103-111.	3.3	48

#	Article	IF	CITATIONS
37	β2-glycoprotein I and oxidative inflammation in early atherogenesis: A progression from innate to adaptive immunity?. Autoimmunity Reviews, 2012, 12, 241-249.	2.5	48
38	Pregnancy Loss and Endometriosis: Pathogenic Role of Anti-Laminin-1 Autoantibodies. Annals of the New York Academy of Sciences, 2005, 1051, 174-184.	1.8	47
39	Inclusion Body Myositis Associated With Human T-Lymphotropic Virus-Type I Infection. Journal of Neuropathology and Experimental Neurology, 2008, 67, 41-49.	0.9	47
40	Expression of vascular endothelial growth factor in tuberculous meningitis. Journal of the Neurological Sciences, 2001, 186, 75-79.	0.3	46
41	Autoantibody-mediated atherosclerosis. Autoimmunity Reviews, 2002, 1, 348-353.	2.5	46
42	Antibodies against heat shock protein 60 derived from Helicobacter pylori: Diagnostic implications in cardiovascular disease. Journal of Autoimmunity, 2007, 29, 106-115.	3.0	46
43	Increase of Serum Angiopoietin-2 During Pregnancy Is Suppressed in Women With Preeclampsia. American Journal of Hypertension, 2005, 18, 1181-1188.	1.0	44
44	Visualization of HTLV-1–Specific Cytotoxic T Lymphocytes in the Spinal Cords of Patients With HTLV-1–Associated Myelopathy/Tropical Spastic Paraparesis. Journal of Neuropathology and Experimental Neurology, 2015, 74, 2-14.	0.9	44
45	HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): A comparative study to identify factors that influence disease progression. Journal of the Neurological Sciences, 2016, 371, 112-116.	0.3	44
46	Enzyme-linked immunosorbent assay for human pulmonary surfactant protein D. Journal of Immunological Methods, 1994, 173, 157-164.	0.6	43
47	Chronic Infections and Atherosclerosis. Clinical Reviews in Allergy and Immunology, 2009, 37, 44-48.	2.9	42
48	MRI studies of spinal visceral larva migrans syndrome. Journal of the Neurological Sciences, 2006, 249, 7-12.	0.3	41
49	Newer Antiphospholipid Antibodies Predict Adverse Outcomes in Patients With Acute Coronary Syndrome. American Journal of Clinical Pathology, 2009, 132, 613-620.	0.4	41
50	Molecular Studies on Phospholipid-Binding Sites and Cryptic Epitopes Appearing on β2-Glycoprotein I Structure Recognized by Anticardiolipin Antibodies. Lupus, 1995, 4, S13-S17.	0.8	40
51	lgG Anti-laminin-1 Autoantibody and Recurrent Miscarriages. American Journal of Reproductive Immunology, 2001, 45, 232-238.	1.2	39
52	Chronic Infections and Atherosclerosis. Annals of the New York Academy of Sciences, 2007, 1108, 594-602.	1.8	39
53	The Orientation of β2GPI on the Plate is Important for the Binding of Anti-β2GPI Autoantibodies by ELISA. Journal of Autoimmunity, 2002, 18, 289-297.	3.0	38
54	Mutations in COA7 cause spinocerebellar ataxia with axonal neuropathy. Brain, 2018, 141, 1622-1636.	3.7	38

#	Article	IF	CITATIONS
55	Clinical Significance of Serum Oxidized Low-Density Lipoprotein/β ₂ -Glycoprotein I Complexes in Patients with Chronic Renal Diseases. Nephron Clinical Practice, 2004, 98, c15-c24.	2.3	36
56	A Simple and Sensitive Radioimmunoassay for Adenosine. Journal of Immunoassay, 1991, 12, 501-519.	0.3	35
57	Proteolytic cleavage of β2-glycoprotein I: reduction of antigenicity and the structural relationship. International Immunology, 2000, 12, 1183-1192.	1.8	35
58	Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations. Acta Neuropathologica Communications, 2018, 6, 105.	2.4	34
59	DNA-alginate complex recognized by autoantibodies against DNA. International Journal of Biological Macromolecules, 1997, 20, 75-77.	3.6	33
60	Oxidized Low-Density Lipoprotein/β2-Glycoprotein I Complexes and Autoantibodies in Patients with Type 2 Diabetes Mellitus. Annals of the New York Academy of Sciences, 2005, 1051, 97-103.	1.8	33
61	Autoimmunity, Infectious Immunity, and Atherosclerosis. Journal of Clinical Immunology, 2009, 29, 714-721.	2.0	33
62	Subclinical Atherosclerosis in Primary Antiphospholipid Syndrome. Annals of the New York Academy of Sciences, 2007, 1108, 475-480.	1.8	32
63	A Novel PET Imaging Using ^{64} Cu-Labeled Monoclonal Antibody against Mesothelin Commonly Expressed on Cancer Cells. Journal of Immunology Research, 2015, 2015, 1-15.	0.9	32
64	Antigenic structures recognized by anti-β2-glycoprotein I auto-antibodies. International Immunology, 2005, 17, 1533-1542.	1.8	31
65	β2-glycoprotein l–anti-β2-glycoprotein I Interaction. Journal of Autoimmunity, 2000, 15, 97-100.	3.0	30
66	Anti-idiotypes to Oxidized LDL Antibodies in Intravenous Immunoglobulin PreparationsPossible Immunomodulation of Atherosclerosis. Autoimmunity, 2003, 36, 91-97.	1.2	30
67	The Role of Innate and Adaptive Immunity to Oxidized Low-Density Lipoprotein in the Development of Atherosclerosis. Annals of the New York Academy of Sciences, 2005, 1051, 442-454.	1.8	30
68	Elevated Serum sFlt-1/Ang-2 Ratio in Women with Preeclampsia. Nephron Clinical Practice, 2007, 106, c43-c50.	2.3	29
69	High Expression of CD244 and SAP Regulated CD8+ T Cell Responses of Patients with HTLV-I Associated Neurologic Disease. PLoS Pathogens, 2009, 5, e1000682.	2.1	29
70	Novel mutation in the replication focus targeting sequence domain of <i><scp>DNMT1</scp></i> causes hereditary sensory and autonomic neuropathy <scp>IE</scp> . Journal of the Peripheral Nervous System, 2013, 18, 89-93.	1.4	29
71	Atherogenic autoantigen: oxidized LDL complexes with ?2-glycoprotein I. Immunobiology, 2003, 207, 17-22.	0.8	28
72	The immunology of atherothrombosis in the antiphospholipid syndrome: Antigen presentation and lipid intracellular accumulation. Autoimmunity Reviews, 2009, 8, 500-505.	2.5	28

#	Article	IF	CITATIONS
73	Preventing autoimmune and infection triggered atherosclerosis for an enduring healthful lifestyle. Autoimmunity Reviews, 2008, 7, 214-222.	2.5	26
74	Atherosclerosis in autoimmune diseases. Current Rheumatology Reports, 2009, 11, 61-69.	2.1	25
75	Neurofilament light mutation causes hereditary motor and sensory neuropathy with pyramidal signs. Journal of the Peripheral Nervous System, 2014, 19, 311-316.	1.4	25
76	A Possible Mechanism of Autoimmuneâ€Mediated infertility in Women with Endometriosis. American Journal of Reproductive Immunology, 2011, 66, 90-99.	1.2	24
77	Inhibition of cell proliferation with antibody-targeted liposomes containing methotrexate-γ-dimyristoylphosphatidylethanolamine. Biochimica Et Biophysica Acta - Biomembranes, 1988, 946, 253-260.	1.4	23
78	Immunization of Naive Mice with Mouse Laminin-1 Affected Pregnancy Outcome in a Mouse Model. American Journal of Reproductive Immunology, 2003, 50, 159-165.	1.2	23
79	Anti-laminin-1 Autoantibodies, Pregnancy Loss and Endometriosis. Clinical and Developmental Immunology, 2004, 11, 261-266.	3.3	23
80	Nicked β2-glycoprotein I binds angiostatin 4.5 (plasminogen kringle 1-5) and attenuates its antiangiogenic property. Blood, 2009, 114, 2553-2559.	0.6	23
81	Research around β2-glycoprotein I: A major target for antiphospholipid antibodies. Autoimmunity, 2005, 38, 377-381.	1.2	21
82	Determination of Oxidized Low-Density Lipoproteins (ox-LDL) versus ox-LDL/beta2GPI Complexes for the Assessment of Autoimmune-Mediated Atherosclerosis. Annals of the New York Academy of Sciences, 2007, 1109, 303-310.	1.8	20
83	Effects of host restriction factors and the HTLV-1 subtype on susceptibility to HTLV-1-associated myelopathy/tropical spastic paraparesis. Retrovirology, 2017, 14, 26.	0.9	20
84	Familial Clusters of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. PLoS ONE, 2014, 9, e86144.	1.1	20
85	Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma. Oncotarget, 2017, 8, 21177-21186.	0.8	20
86	Minocycline modulates antigen-specific CTL activity through inactivation of mononuclear phagocytes in patients with HTLV-I associated neurologic disease. Retrovirology, 2012, 9, 16.	0.9	19
87	Satoyoshi syndrome has antibody against brain and gastrointestinal tissue. Muscle and Nerve, 2007, 36, 400-403.	1.0	18
88	Immunogenic Oxidized Low-density Lipoprotein/β2-glycoprotein I Complexes in the Diagnostic Management of Atherosclerosis. Clinical Reviews in Allergy and Immunology, 2009, 37, 12-19.	2.9	17
89	7-Ketocholesteryl-9-carboxynonanoate induced nuclear factor-kappa B activation in J774A.1 macrophages. Life Sciences, 2010, 87, 651-657.	2.0	17
90	Clinical and genetic features of Charcotâ€Marieâ€Tooth disease 2F and hereditary motor neuropathy 2B in Japan. Journal of the Peripheral Nervous System, 2018, 23, 40-48.	1.4	17

#	Article	IF	CITATIONS
91	Anti-β 2 -Glycoprotein I Autoantibodies and Atherosclerosis. International Reviews of Immunology, 2002, 21, 51-66.	1.5	15
92	Antiphospholipid Antibodies in Patients with Coronary Artery Disease: New Cardiac Risk Factors?. Annals of the New York Academy of Sciences, 2007, 1108, 466-474.	1.8	15
93	Anti-high Mobility Group Box 1 Antibody Ameliorates Albuminuria in MRL/lpr Lupus-Prone Mice. Molecular Therapy - Methods and Clinical Development, 2017, 6, 31-39.	1.8	15
94	Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P). Viruses, 2022, 14, 136.	1.5	15
95	Positron Emission Tomography to Elucidate Pharmacokinetic Differences of Regioisomeric Retinoid X Receptor Agonists. ACS Medicinal Chemistry Letters, 2015, 6, 334-338.	1.3	14
96	Enhanced cellular uptake of lactosomes using cell-penetrating peptides. Science and Technology of Advanced Materials, 2016, 17, 245-252.	2.8	14
97	β2-GPI-dependent and independent binding of anticardiolipin antibodies in patients with recurrent spontaneous abortions. Journal of Clinical Laboratory Analysis, 1994, 8, 255-259.	0.9	13

98 Anticardiolipin Antibodies in Patients With Pregnancy Loss Induce Factor Xa Production in the

#	Article	IF	CITATIONS
109	Enzyme Immunoassay for Mabuterol, A Selective β2-Adrenergic Stimulant in the Trachea. Journal of Immunoassay, 1985, 6, 261-276.	0.3	10
110	Unilateral toe-walking secondary to intramuscular hemangioma in the gastrocnemius. Neurology, 2005, 65, E15-E15.	1.5	10
111	Rosuvastatin Treatment is Associated with a Decrease of Serum Oxidised Low-Density Lipoprotein/Beta2-Glycoprotein I Complex Concentration in Type 2 Diabetes. British Journal of Diabetes and Vascular Disease, 2010, 10, 292-299.	0.6	10
112	A purification system for 64Cu produced by a biomedical cyclotron for antibody PET imaging. Journal of Radioanalytical and Nuclear Chemistry, 2013, 298, 295-300.	0.7	10
113	Novel single hain variant of antibody against mesothelin established by phage library. Cancer Science, 2019, 110, 2722-2733.	1.7	10
114	Antioxidative attributes of rice bran extracts in ameliorative effects of atherosclerosis-associated risk factors. Heliyon, 2020, 6, e05743.	1.4	10
115	Monoclonal Antibody for Calcitriol (l α,25-Dihydroxyvitamin D3). Journal of Biochemistry, 1985, 98, 991-998.	0.9	9
116	Different pattern of HSP47 expression in skeletal muscle of patients with neuromuscular diseases. Neuromuscular Disorders, 2007, 17, 221-226.	0.3	9
117	Ectopic calcification: importance of common nanoparticle scaffolds containing oxidized acidic lipids. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 441-450.	1.7	9
118	<i>Toxocara canis</i> myelitis involving the lumbosacral region: a case report. Journal of Spinal Cord Medicine, 2017, 40, 241-245.	0.7	9
119	The CC chemokine ligand (CCL) 1, upregulated by the viral transactivator Tax, can be downregulated by minocycline: possible implications for long-term treatment of HTLV-1-associated myelopathy/tropical spastic paraparesis. Virology Journal, 2017, 14, 234.	1.4	9
120	Genome wide association study of HTLV-1–associated myelopathy/tropical spastic paraparesis in the Japanese population. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	9
121	Real-time monitoring of tumor progression and drug responses in a preclinical mouse model of prostate cancer. Oncotarget, 2016, 7, 33025-33034.	0.8	9
122	The application of shotgun metagenomics to the diagnosis of granulomatous amoebic encephalitis due to Balamuthia mandrillaris: a case report. BMC Neurology, 2021, 21, 392.	0.8	9
123	Characterization of a Murine Anti-laminin-1 Monoclonal Antibody (AK8) Produced by Immunization with Mouse-derived Laminin-1. Clinical and Developmental Immunology, 2005, 12, 67-73.	3.3	8
124	Expression of the Heparin-Binding Growth Factor Midkine in the Cerebrospinal Fluid of Patients with Neurological Disorders. Internal Medicine, 2008, 47, 83-89.	0.3	8
125	7-Ketocholesteryl-9-carboxynonanoate enhances the expression of ATP-binding cassette transporter A1 via CD36. Atherosclerosis, 2013, 226, 102-109.	0.4	8
126	The lipid moiety 7-ketocholesteryl-9-carboxynonanoate mediates binding interaction of oxLDL to LOX-1 and upregulates ABCA1 expression through PPARÎ ³ . Life Sciences, 2017, 177, 27-40.	2.0	8

#	Article	IF	CITATIONS
127	Clinical presentation of axial myopathy in two siblings with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). BMC Neurology, 2015, 15, 18.	0.8	7
128	New type of encephalomyelitis responsive to trimethoprim/sulfamethoxazole treatment in Japan. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e143.	3.1	7
129	Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1487-1492.	0.7	7
130	Cytoprotective and Cytotoxic Effects of Rice Bran Extracts in Rat H9c2(2-1) Cardiomyocytes. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-12.	1.9	7
131	A Novel 89Zr-labeled DDS Device Utilizing Human IgG Variant (scFv): "Lactosome―Nanoparticle-Based Theranostics for PET Imaging and Targeted Therapy. Life, 2021, 11, 158.	1.1	7
132	IMMUNOLOGY OF ANTI-PHOSPHOLIPID ANTIBODIES AND COFACTORS. , 2004, , 1081-1105.		7
133	Use of various methods for anticardiolipin detection in the updated American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus: Comment on the letter by Hochberg. Arthritis and Rheumatism, 1998, 41, 1326-1327.	6.7	6
134	Laminin-1 (LM-111) in preeclampsia and systemic lupus erythematosus. Autoimmunity, 2013, 46, 14-20.	1.2	6
135	Participation of α _{Ilb} β ₃ in Platelet Microparticle Generation by Collagen plus Thrombin. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 31-37.	0.5	5
136	7-Ketocholesteryl-9-carboxynonanoate enhances ATP binding cassette transporter A1 expression mediated by PPARÎ ³ in THP-1 macrophages. Atherosclerosis, 2014, 234, 461-468.	0.4	5
137	Partial Deficiency of Emerin Caused by a Splice Site Mutation in <i>EMD</i> . Internal Medicine, 2014, 53, 1563-1568.	0.3	5
138	Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. PLoS Neglected Tropical Diseases, 2020, 14, e0008361.	1.3	5
139	An NEFH founder mutation causes broad phenotypic spectrum in multiple Japanese families. Journal of Human Genetics, 2022, 67, 399-403.	1.1	5
140	An experimental model of nephritis induced by calf serum injection in mice The Japanese Journal of Pharmacology, 1984, 36, 223-234.	1.2	4
141	Detection and clinical significance of acetoneinsoluble liver cell membrane antigen in sera of patients with chronic active liver diseases. Gastroenterologia Japonica, 1985, 20, 37-47.	0.4	4
142	Postinfectious immunodeficiency and autoimmunity: pathogenic and clinical values and implications. Expert Review of Clinical Immunology, 2007, 3, 323-331.	1.3	4
143	Atherosclerosis and Autoimmunity. Clinical Reviews in Allergy and Immunology, 2009, 37, 1-3.	2.9	4
144	Histopathological differences between human T-lymphotropic virus type 1-positive and human T-lymphotropic virus type 1-negative polymyositis. Clinical and Experimental Neuroimmunology, 2011, 2, 12-24.	0.5	4

#	Article	IF	CITATIONS
145	Recombinant domain V of Â2-glycoprotein I inhibits the formation of a 7-ketocholesteryl-9-carboxynonanoate and Â2-glycoprotein I complex. Journal of Biochemistry, 2011, 149, 35-42.	0.9	4
146	Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases. Cells, 2021, 10, 707.	1.8	4
147	Selfâ€interaction of soluble and surfaceâ€bound β ₂ â€glycoprotein I and its enhancement by lupus anticoagulants. FEBS Letters, 2008, 582, 3308-3312.	1.3	3
148	Atherosclerosis in primary antiphospholipid syndrome. Expert Review of Clinical Immunology, 2008, 4, 53-60.	1.3	3
149	Dynamic acquisition of HTLV-1 tax protein by mononuclear phagocytes: Role in neurologic disease. Journal of Neuroimmunology, 2017, 304, 43-50.	1.1	3
150	Mutants of β2-glycoprotein I: Their features and potent applications. Best Practice and Research in Clinical Rheumatology, 2018, 32, 572-590.	1.4	3
151	Rapid and specific detection of oxidized LDL/β2GPI complexes via facile lateral flow immunoassay. Heliyon, 2020, 6, e04114.	1.4	3
152	Anti-Human T-Cell Leukemia Virus Type 1 (HTLV-1) Antibody Assays in Cerebrospinal Fluid for the Diagnosis of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. Journal of Clinical Microbiology, 2021, 59, .	1.8	3
153	New impacts of cutaneous lupus erythematosus for global standard concepts. Autoimmunity Reviews, 2009, 8, 439-440.	2.5	2
154	<i>Tithonia diversifolia</i> â€derived orizabin suppresses cell adhesion, differentiation, and oxidized LDL accumulation by Akt signaling suppression via PTEN promotion in THPâ€1 cells. Journal of Food Biochemistry, 2020, 44, e13268.	1.2	2
155	High Prevalence of HTLV-1 Carriers Among the Elderly Population in Kagoshima, a Highly Endemic Area in Japan. AIDS Research and Human Retroviruses, 2022, 38, 363-369.	0.5	2
156	Complex hereditary peripheral neuropathies caused by novel variants in mitochondrial-related nuclear genes. Journal of Neurology, 2022, 269, 4129-4140.	1.8	2
157	Antiphospholipid Syndrome Internal Medicine, 1999, 38, 170-173.	0.3	1
158	Î ² 2-GLYCOPROTEIN I AUTOANTIBODIES. , 2007, , 687-693.		1
159	Endemic impact of human T cell leukemia virus type 1 screening in bone allografts. Cell and Tissue Banking, 2016, 17, 555-560.	0.5	1
160	PET Imaging Utilizing ⁸⁹ Zr-labeled Human Antibody Variant and Theranostic Technologies Provided by a Novel DDS Carrier. Drug Delivery System, 2018, 33, 214-222.	0.0	1
161	>Sera Anti-P53 Antibody Provides New Information Which Explains the Link Between Diabetes and Cancer. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 325-331.	1.1	1
162	Neural bystander damage by infiltrating virus-infected T cells and the cytotoxic T lymphocytes in HTLV-I-associated neurological disease. Retrovirology, 2011, 8, .	0.9	0

#	Article	IF	CITATIONS
163	Novel mutations identified in patients with a mild phenotype of Ullrich congenital muscular dystrophy through targeted next-generation sequencing. Neurology and Clinical Neuroscience, 2013, 1, 148-153.	0.2	0
164	β2-Glycoprotein I Autoantibodies. , 2014, , 689-698.		0
165	Peripheral neuropathy in a case with CADASIL: a case report. BMC Neurology, 2018, 18, 134.	0.8	0